BNO--29/5

BIONOMICS LIMITED 2002-05-29 ASX-SIGNAL-G
----------------------------------------------------------------------
HOMEX - Adelaide
----------------------------------------------------------------------
+++++++++++++++++++++++++
Bionomics Limited (ASX:BNO), today announced progress of its product
development collaboration with the European and US-based company
Genmab A/S to create and develop fully human antibodies to
angiogenesis targets identified by Bionomics.
----------------------------------------------------------------------
Just two months into the collaboration, Bionomics' CEO and Managing
Director, Deborah Rathjen said Bionomics and Genmab were progressing
the development of antibody products by including a third Bionomics'
target, one more than was initially proposed when the collaborative
development deal was announced in March. Dr Rathjen also said that
Bionomics and Genmab had formalized the steering and research
committees that will manage the collaborative program.
----------------------------------------------------------------------
"We are now on track to seeing a first antibody product entering
clinical phase within twoyears," said Dr Rathjen. "The three targets
that are subject to the joint development program include a target in
a chromosomal region that is amplified in several human cancers,
particularly in lung and liver tumours."
----------------------------------------------------------------------
Industry estimates suggest that the treatment of lung cancer and
liver cancer represent markets of at least US$2 billion each, on a
global basis.
----------------------------------------------------------------------
All three targets are associated with the process of angiogenesis,
which is involved in the growth of cancer and inflammatory diseases.
----------------------------------------------------------------------
"This is a very important partnership for Bionomics as the world
antibody market is currently worth more than US$3 billion. Antibody
products have shorter development times when compared with typical
small molecule drug development. Working with Genmab will see
Bionomics accelerate its product rollout from the lab to clinical use
and human benefit," said Dr Rathjen.
----------------------------------------------------------------------
FOR FURTHER INFORMATION PLEASE CONTACT:
----------------------------------------------------------------------
Dr Deborah Rathjen
CEO & MANAGING DIRECTOR
Bionomics Limited
Ph: +61 8 8354 6101
----------------------------------------------------------------------
Or visit the Bionomics website at www.bionomics.com.au
----------------------------------------------------------------------